Paul Tudor Jones’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.95M | Buy |
+195,128
| New | +$1.76M | ﹤0.01% | 1961 |
|
|
2026
Q1 | – | Sell |
-114,541
| Closed | -$890K | – | 3616 |
|
|
2025
Q4 | $893K | Buy |
114,541
+16,366
| +17% | +$118K | ﹤0.01% | 2350 |
|
|
2025
Q3 | $745K | Sell |
98,175
-80,909
| -45% | -$674K | ﹤0.01% | 2467 |
|
|
2025
Q2 | $1.6M | Buy |
179,084
+74,042
| +70% | +$690K | ﹤0.01% | 1820 |
|
|
2025
Q1 | $788K | Buy |
105,042
+5,592
| +6% | +$45.1K | ﹤0.01% | 1976 |
|
|
2024
Q4 | $748K | Buy |
+99,450
| New | +$755K | ﹤0.01% | 1942 |
|
|
2024
Q3 | – | Sell |
-103,002
| Closed | -$637K | – | 2711 |
|
|
2024
Q2 | $637K | Buy |
+103,002
| New | +$568K | ﹤0.01% | 1696 |
|
|
2024
Q1 | – | Sell |
-209,905
| Closed | -$1.26M | – | 2224 |
|
|
2023
Q4 | $1.26M | Buy |
209,905
+115,470
| +122% | +$669K | 0.01% | 1337 |
|
|
2023
Q3 | $669K | Buy |
94,435
+17,773
| +23% | +$128K | 0.01% | 1528 |
|
|
2023
Q2 | $540K | Buy |
+76,662
| New | +$615K | 0.01% | 1672 |
|
|
2022
Q4 | – | Sell |
-92,879
| Closed | -$1.17M | – | 2382 |
|
|
2022
Q3 | $1.17M | Buy |
92,879
+68,818
| +286% | +$886K | 0.03% | 816 |
|
|
2022
Q2 | $255K | Buy |
+24,061
| New | +$248K | 0.01% | 1672 |
|
|
2021
Q4 | – | Sell |
-131,066
| Closed | -$1.88M | – | 2397 |
|
|
2021
Q3 | $1.88M | Buy |
131,066
+68,168
| +108% | +$1.08M | 0.03% | 754 |
|
|
2021
Q2 | $994K | Buy |
62,898
+4,981
| +9% | +$67.7K | 0.02% | 864 |
|
|
2021
Q1 | $589K | Buy |
+57,917
| New | +$597K | 0.01% | 1080 |
|
|
2020
Q2 | – | Sell |
-49,102
| Closed | -$98K | – | 1171 |
|
|
2020
Q1 | $98K | Sell |
49,102
-104,005
| -68% | -$286K | 0.01% | 929 |
|
|
2019
Q4 | $528K | Buy |
153,107
+93,959
| +159% | +$236K | 0.02% | 697 |
|
|
2019
Q3 | $169K | Buy |
59,148
+22,281
| +60% | +$69.3K | 0.01% | 972 |
|
|
2019
Q2 | $140K | Buy |
+36,867
| New | +$222K | ﹤0.01% | 1009 |
|
|
2017
Q4 | – | Sell |
-102,494
| Closed | -$537K | – | 1082 |
|
|
2017
Q3 | $537K | Buy |
102,494
+60,566
| +144% | +$310K | 0.01% | 614 |
|
|
2017
Q2 | $233K | Buy |
+41,928
| New | +$255K | 0.01% | 837 |
|
|
2016
Q4 | – | Sell |
-11,137
| Closed | -$49K | – | 1391 |
|
|
2016
Q3 | $49K | Sell |
11,137
-5,550
| -33% | -$22.2K | ﹤0.01% | 1370 |
|
|
2016
Q2 | $47K | Sell |
16,687
-108,901
| -87% | -$338K | ﹤0.01% | 1552 |
|
|
2016
Q1 | $355K | Buy |
125,588
+114,403
| +1,023% | +$507K | 0.01% | 1183 |
|
|
2015
Q4 | $115K | Sell |
11,185
-18,350
| -62% | -$182K | ﹤0.01% | 1520 |
|
|
2015
Q3 | $337K | Buy |
29,535
+16,227
| +122% | +$217K | 0.01% | 1020 |
|
|
2015
Q2 | $199K | Buy |
+13,308
| New | +$151K | 0.01% | 1336 |
|
Other funds holding BCRX
RCM
DM
TCM
PA
JT
VPC
Paul Tudor Jones's BCRX Position: Q2 2026 in Review
Paul Tudor Jones opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 195,128 shares worth $1.95M. The stake represents ﹤0.01% of the portfolio and ranks #1961 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in BCRX as recently as Q4 2025.
Paul Tudor Jones first reported a position in BCRX in Q2 2015 and has held it in 27 quarters since. 316 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.
- Paul Tudor Jones held 195,128 shares of BioCryst Pharmaceuticals worth $1.95M as of Q2 2026.
- BioCryst Pharmaceuticals was a new Paul Tudor Jones position in Q2 2026.
- BioCryst Pharmaceuticals made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1961 holding.
- Paul Tudor Jones first reported a position in BioCryst Pharmaceuticals in Q2 2015 and has held it in 27 quarters since.
- 316 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.
Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.